On-Chip Drug Screening and Nanomedicine Applications via (L)SPR

Drug screening is the first phase of a drug development process taking 10 to 15 years for detecting potential drug candidates. Screening of candidates on drug targets is a random process and functions of drugs are not known in most trials, therefore traditional drug screening is not efficient and expedite process. In vitro nanomedicine and drug screening platforms provide significant contribution to thescreening approach byaccelerating the overall process prior to in vivo animal and clinical experiments [1,2]. Microfluidic systems and microdevices have been utilized in recent years for drug screening analysis since they can be easily adapted to in vitro biological systems and bioanalitical tools. Advancements in miniaturized devices, such as microfluidic labon-a-chip tools have significantly increased the accuracy and cost-effectiveness of sample analysis in pharmaceutical field. In addition, these technologies show promise for pharmaceutical and drug discovery field owing to cost-effective, rapid , portable, low sample volume and high-throughput analysis features [3,4].